Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization.
Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that time. Stifel argued that Roivant offers multiple late-stage opportunities across specialty autoimmune and pulmonary diseases. The firm projects around $9 billion in ownership-adjusted sales for Roivant by 2037.
Can Roivant turn its multi-asset strategy into long-term revenue growth? Anything is possible. Let’s dive in.
Pressmaster/Shutterstock.com
Lisraya Gives Roivant a New Major Commercial Opportunity—and a Test
Roivant Sciences Ltd.’s most immediate opportunity is Lisraya (brepocitinib). The FDA approved Lisraya on August 27 for adults with dermatomyositis. The drug became the first FDA-approved oral treatment for the rare disease.
Roivant sees potential in brepocitinib beyond its initial indication for adults with dermatomyositis. The compound is being evaluated in non-infectious uveitis, and Roivant expects topline data from a Phase 3 study in the second half of 2026.
Roivant is also evaluating brepocitinib in cutaneous sarcoidosis and lichen planopilaris. Phase 3 data from the cutaneous sarcoidosis study is expected in 2028. Meanwhile, enrollment in Part 1 of a Phase 2b/3 study of the compound in lichen planopilaris is on course.
The Lisraya approval provides a fresh test of Roivant’s commercial execution as the company seeks to translate another clinical success into meaningful revenue. The drug’s approval alone does not guarantee rapid adoption. Considering that Lisraya targets a rare disease, physician awareness, reimbursement, and competition will influence the pace of its uptake.
Roivant’s Multiple Programs Carry Opportunities and Risks
Beyond brepocitinib (Lisraya), Roivant Sciences Ltd. has a broad pipeline targeting multiple disease areas.
For instance, IMVT-1402, an anti-FcRn antibody, is advancing in several autoimmune indications. Clinical updates are expected in 2026 and potentially registrational trials in diseases like Graves’ disease, myasthenia gravis, and difficult-to-treat rheumatoid arthritis.
In another program, mosliciguat has produced positive Phase 2 results in pulmonary hypertension associated with interstitial lung disease. The PHocus study met its primary endpoint, with a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16. The study also showed improvements in six-minute walk distance and NT-proBNP. Roivant has subsequently unveiled a Phase 3 program.
Roivant does have substantial financial resources to fund its programs. The company reported $3.9 billion in cash, cash equivalents, restricted cash, and marketable securities at June 30. In July, Genevant and Arbutus received an aggregate $950 million payment from Moderna through a patent infringement settlement, with Genevant receiving $771.6 million. That payment further strengthened the company’s cash position.
Still, Roivant’s multiple programs require successful trials, regulatory approval, and commercial execution before they can justify the long-term sales expectations behind the valuation.
Roivant Sees Rising Hedge Fund Interest Amid Short Seller Skepticism
Elite investors have increased their exposure to Roivant Sciences Ltd. in recent quarters. At the end of Q2, 64 hedge funds had positions in Roivant, up from 60 in Q1 and 52 in Q4.
However, while the broader hedge fund interest increased, individual funds moved in different directions in the latest quarter’s trades. QVT Financial reduced its stake by 6% compared to the previous quarter, though it remained the top holder with 23.7 million shares. Farallon Capital increased its position 48% to 14.3 million shares, and Adage Capital Management cut its exposure 20% to 10.3 million shares.
Short interest reflects deeper skepticism. As of August 31, 33.5 million Roivant shares were shorted, with 3.8 days to cover. That was equal to 5.09% of the public float, reflecting a 9.54% increase in bearish bets from the previous reading.
The investor positioning points to a company attracting more elite holders while still facing short seller doubts. The ultimate test for Roivant is whether its multi-asset strategy can support the long-term growth expectations reflected in Stifel’s valuation.
READ NEXT: Northrop Grumman (NOC) Secures $4.8 Billion Army Contract. Execution Is the Bigger Test and Pentagon Adds $13.4 Billion to Boeing (BA) Contract. That Isn’t an Immediate Financial Windfall.
Hedge Fund Resource Center